
Why payment processors treat peptides as "riskier than gambling", per gray-market peptide CEO
Thanks to our partners:
Superpower - https://superpower.com
CareValidate - https://carevalidate.com
FDA warning letter: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peptide-partners-llc-735063-08242026
In episode 84, Jonathan Stern talks with Zak David, founder of Peptide Partners, one of the largest research-peptide sellers in the US. This is Zak's first and only interview discussing Peptide Partners' FDA warning letter! We get into why payment processors consider research peptides riskier than gambling, what advice he'd give Hims, and whether the gray market will be even bigger in three years. Zak also responds to Martin Shkreli's claim that peptides are setting Western medicine back 70 years.
00:00 - Sponsors: Superpower + CareValidate
01:49 - How Zak found peptides
04:19 - 80% of vials now "fill-finished" in the US
06:15 - Just under 100K customers all-time
08:48 - Retatrutide is #1
12:33 - Zak's take on the FDA letter
20:25 - Peptides "riskier than gambling" to payment processors
25:01 - Why they now test more than 10 vials per batch
31:06 - All China today, India lab coming in December
31:04 - Peptide Partners' supply chain today
34:58 - American-made peptide potential pricing
40:48 - Grindr's $250 million deal
46:32 - TSA agent recognized his peptide vials
49:48 - Zak's advice to Hims & Andrew Dudum
52:22 - Why Shkreli is wrong about peptides
Disclaimer: This podcast is for informational and entertainment purposes only. Nothing discussed should be considered financial, investment, or legal advice. Always consult with a qualified professional before making financial decisions.
Altri episodi di "Hims House"



Non perdere nemmeno un episodio di “Hims House”. Iscriviti all'app gratuita GetPodcast.








